The Inflammation Biomarker GlycA Reflects Plasma N-Glycan Branching
- PMID: 36254612
- PMCID: PMC10726709
- DOI: 10.1093/clinchem/hvac160
The Inflammation Biomarker GlycA Reflects Plasma N-Glycan Branching
Abstract
Background: GlycA is a nuclear magnetic resonance (NMR) signal in plasma that correlates with inflammation and cardiovascular outcomes in large data sets. The signal is thought to originate from N-acetylglucosamine (GlcNAc) residues of branched plasma N-glycans, though direct experimental evidence is limited. Trace element concentrations affect plasma glycosylation patterns and may thereby also influence GlycA.
Methods: NMR GlycA signal was measured in plasma samples from 87 individuals and correlated with MALDI-MS N-glycomics and trace element analysis. We further evaluated the genetic association with GlycA at rs13107325, a single nucleotide polymorphism resulting in a missense variant within SLC39A8, a manganese transporter that influences N-glycan branching, both in our samples and existing genome-wide association studies data from 22 835 participants in the Women's Health Study (WHS).
Results: GlycA signal was correlated with both N-glycan branching (r2 ranging from 0.125-0.265; all P < 0.001) and copper concentration (r2 = 0.348, P < 0.0001). In addition, GlycA levels were associated with rs13107325 genotype in the WHS (β [standard error of the mean] = -4.66 [1.2674], P = 0.0002).
Conclusions: These results provide the first direct experimental evidence linking the GlycA NMR signal to N-glycan branching commonly associated with acute phase reactive proteins involved in inflammation.
© American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
Figures



References
-
- Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. . GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem 2015;61:714–23. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL160799/HL/NHLBI NIH HHS/United States
- RF1 AG062181/AG/NIA NIH HHS/United States
- R01 HL043851/HL/NHLBI NIH HHS/United States
- UE2 EH001329/EH/NCEH CDC HHS/United States
- HL043851 and HL080467, HL099355/HL/NHLBI NIH HHS/United States
- CA047988 and UM1CA182913/CA/NCI NIH HHS/United States
- R01 CA047988/CA/NCI NIH HHS/United States
- K24 HL136852/HL/NHLBI NIH HHS/United States
- R01 HL134811/HL/NHLBI NIH HHS/United States
- T32 MH112485/MH/NIMH NIH HHS/United States
- RF1AG062181/GF/NIH HHS/United States
- R24 GM137763/GM/NIGMS NIH HHS/United States
- U19 FD007089/FD/FDA HHS/United States
- UM1 CA182913/CA/NCI NIH HHS/United States
- K08 MH128712/MH/NIMH NIH HHS/United States
- R01 HL080467/HL/NHLBI NIH HHS/United States
- R01 HL117861/HL/NHLBI NIH HHS/United States
- RC1 HL099355/HL/NHLBI NIH HHS/United States